Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 11, Issue 9, Pages 854-862Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152011797655050
Keywords
Hypoxia; Hypoxia inducible factor; Sphingosine 1-Phosphate; Sphingosine kinase 1; cancer therapy
Categories
Funding
- Institut National du Cancer (INCa)
- La Ligue Nationale Contre le Cancer (Equipe labellisee)
- La Ligue Contre le Cancer
- Association pour la Recherche sur le Cancer (ARC)
- Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)
- Universite Paul Sabatier de Toulouse
Ask authors/readers for more resources
Hypoxia, defined as reduced tissue oxygen concentration, is a characteristic of solid tumors and is an indicator of unfavorable diagnosis in patients. At the cellular level, the adaptation to hypoxia is under the control of two related transcription factors, HIF-1 alpha and HIF-2 alpha (Hypoxia-Inducible Factor), which activate expression of genes promoting angiogenesis, metastasis, increased tumor growth and resistance to treatments. A role for HIF-1 alpha and HIF-2 alpha is also emerging in hematologic malignancies such as lymphoma and leukemia. Recent studies have identified the sphingosine kinase 1/sphingosine 1-phosphate (SphK1/S1P) signaling pathway - which elicits various cellular processes including cell proliferation, cell survival or angiogenesis - as a new regulator of HIF-1 alpha or HIF-2 alpha activity. This review will consider how targeting the SphK1/S1P signaling could represent an attractive strategy for therapeutic intervention in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available